BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 29724189)

  • 1. Pretherapeutic FDG-PET total metabolic tumor volume predicts response to induction therapy in pediatric Hodgkin's lymphoma.
    Rogasch JMM; Hundsdoerfer P; Hofheinz F; Wedel F; Schatka I; Amthauer H; Furth C
    BMC Cancer; 2018 May; 18(1):521. PubMed ID: 29724189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic tumor volume by positron emission tomography/computed tomography as a clinical parameter to determine therapeutic modality for early stage Hodgkin's lymphoma.
    Song MK; Chung JS; Lee JJ; Jeong SY; Lee SM; Hong JS; Chong A; Moon JH; Kim JH; Lee SM; Kim SJ; Shin HJ
    Cancer Sci; 2013 Dec; 104(12):1656-61. PubMed ID: 24033666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma - Data from the prospective, multicenter phase III HD16 trial.
    van Heek L; Stuka C; Kaul H; Müller H; Mettler J; Hitz F; Baues C; Fuchs M; Borchmann P; Engert A; Dietlein M; Voltin CA; Kobe C
    BMC Cancer; 2022 Jun; 22(1):672. PubMed ID: 35717166
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Georgi TW; Kluge R; Kurch L; Chavdarova L; Hasenclever D; Stoevesandt D; Pelz T; Landman-Parker J; Wallace WH; Karlen J; Fernández-Teijeiro A; Cepelova M; Fosså A; Balwierz W; Attarbaschi A; Ammann RA; Pears J; Hraskova A; Uyttebroeck A; Beishuizen A; Dieckmann K; Leblanc T; Daw S; Baumann J; Körholz D; Sabri O; Mauz-Körholz C
    J Nucl Med; 2018 Oct; 59(10):1524-1530. PubMed ID: 29653979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of Recurrence and Mortality of Locally Advanced Esophageal Cancer Patients Using Pretreatment F-18 FDG PET/CT Parameters: Intratumoral Heterogeneity, SUV, and Volumetric Parameters.
    Chang S; Kim SJ
    Cancer Biother Radiopharm; 2016 Feb; 31(1):1-6. PubMed ID: 26844846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of baseline metabolic tumor volume (MTV) for forecasting chemotherapy outcome in early-stage unfavorable Hodgkin lymphoma: Data from the phase III HD17 trial.
    van Heek L; Weindler J; Gorniak C; Kaul H; Müller H; Mettler J; Baues C; Fuchs M; Borchmann P; Ferdinandus J; Dietlein M; Voltin CA; Kobe C; Roth KS
    Eur J Haematol; 2023 Dec; 111(6):881-887. PubMed ID: 37644732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different
    El-Hennawy G; Moustafa H; Omar W; Elkinaai N; Kamel A; Zaki I; Farid N; El-Kholy E
    Pediatr Blood Cancer; 2020 Nov; 67(11):e28605. PubMed ID: 32706520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of Metabolic Tumor Volume at Baseline and Reduction of Mean Standardized Uptake Value in
    Higuchi T; Fujimoto Y; Ozawa H; Bun A; Fukui R; Miyagawa Y; Imamura M; Kitajima K; Yamakado K; Miyoshi Y
    Ann Surg Oncol; 2019 Jul; 26(7):2175-2183. PubMed ID: 30941655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP
    Borchmann P; Haverkamp H; Lohri A; Mey U; Kreissl S; Greil R; Markova J; Feuring-Buske M; Meissner J; Dührsen U; Ostermann H; Keller U; Maschmeyer G; Kuhnert G; Dietlein M; Kobe C; Eich H; Baues C; Stein H; Fuchs M; Diehl V; Engert A
    Lancet Oncol; 2017 Apr; 18(4):454-463. PubMed ID: 28236583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Semiquantitative analysis of interim
    Ribeiro T; Marques A; Ferreira G; Castro C; Tavares M; Espírito-Santo A; Moreira C; Mariz J
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2021; 40(5):281-286. PubMed ID: 34425968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of baseline and interim [
    Yadgarov MY; Dunaykin MM; Shestopalov GI; Kailash C; Kireeva ED; Myakova NV; Likar YN
    Eur J Nucl Med Mol Imaging; 2024 Feb; ():. PubMed ID: 38351389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy Response Assessment by FDG-PET-CT in Early-stage Classical Hodgkin Lymphoma: Moving Beyond the Five-Point Deauville Score.
    Milgrom SA; Dong W; Akhtari M; Smith GL; Pinnix CC; Mawlawi O; Rohren E; Garg N; Chuang H; Yehia ZA; Reddy JP; Gunther JR; Khoury JD; Suki T; Osborne EM; Oki Y; Fanale M; Dabaja BS
    Int J Radiat Oncol Biol Phys; 2017 Feb; 97(2):333-338. PubMed ID: 28068241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of F-18 FDG PET/CT in evaluating the impact of HIV infection on tumor burden and therapy outcome in patients with Hodgkin lymphoma.
    Lawal IO; Nyakale NE; Harry LM; Modiselle MR; Ankrah AO; Msomi AP; Mokgoro NP; Boshomane TG; de Wiele CV; Sathekge MM
    Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):2025-2033. PubMed ID: 28660348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interim-treatment quantitative PET parameters predict progression and death among patients with Hodgkin's disease.
    Tseng D; Rachakonda LP; Su Z; Advani R; Horning S; Hoppe RT; Quon A; Graves EE; Loo BW; Tran PT
    Radiat Oncol; 2012 Jan; 7():5. PubMed ID: 22260710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.
    Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G
    Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Hassan A; Siddique M; Bashir H; Riaz S; Wali R; Mahreen A; Nawaz MK
    Eur J Nucl Med Mol Imaging; 2017 Jul; 44(7):1198-1206. PubMed ID: 28229191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of baseline metabolic tumor volume in children and adolescents with intermediate-risk Hodgkin lymphoma treated with chemo-radiation therapy: FDG-PET parameter analysis in a subgroup from COG AHOD0031.
    Milgrom SA; Kim J; Chirindel A; Kim J; Pei Q; Chen L; Buxton A; Kessel S; Leal J; McCarten KM; Hoppe BS; Wolden SL; Schwartz CL; Friedman DL; Kelly KM; Cho SY
    Pediatr Blood Cancer; 2021 Sep; 68(9):e29212. PubMed ID: 34245210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Whole-body MRI for staging and interim response monitoring in paediatric and adolescent Hodgkin's lymphoma: a comparison with multi-modality reference standard including
    Latifoltojar A; Punwani S; Lopes A; Humphries PD; Klusmann M; Menezes LJ; Daw S; Shankar A; Neriman D; Fitzke H; Clifton-Hadley L; Smith P; Taylor SA
    Eur Radiol; 2019 Jan; 29(1):202-212. PubMed ID: 29948084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma.
    Kobe C; Kuhnert G; Kahraman D; Haverkamp H; Eich HT; Franke M; Persigehl T; Klutmann S; Amthauer H; Bockisch A; Kluge R; Wolf HH; Maintz D; Fuchs M; Borchmann P; Diehl V; Drzezga A; Engert A; Dietlein M
    J Clin Oncol; 2014 Jun; 32(17):1776-81. PubMed ID: 24799482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.